Marcus Wheeler, MD
Neurology with Special Qualifications in Child Neurology · Kalispell, MTNPI 1750544490
Payments from drug & device makers
Across 41 payments — averaging $153.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$4K
- Immedica Pharma US, Inc.$1K
- Sarepta Therapeutics, Inc.$281
- Livanova USA, Inc.$230
- Sunovion Pharmaceuticals Inc.$90
- Zogenix Inc.$73
- plus $198 from 8 others
What the payments were for
- Consulting fees$75012%
- Speaking & faculty fees$4,34569%
- Food & beverage$1,21819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 9 | $4,139 |
| Immedica Pharma US, Inc. | 3 | $1,301 |
| Sarepta Therapeutics, Inc. | 4 | $281 |
| Livanova USA, Inc. | 7 | $230 |
| Sunovion Pharmaceuticals Inc. | 6 | $90 |
| Zogenix Inc. | 1 | $73 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Greenwich Biosciences, Inc. | 2 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $28 |
| Genentech USA, Inc. | 1 | $19 |
| ITF Therapeutics LLC | 1 | $17 |
| Strongbridge US Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZTALMY$1,267
How this compares
Too few neurology with special qualifications in child neurology providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnfiClobazam | 11 | $38,723 |
| VimpatLacosamide | 11 | $35,871 |
| Lamictal XrLamotrigine | 17 | $29,316 |
| Levetiracetam | 260 | $8,570 |
| Oxcarbazepine | 135 | $7,650 |
| Carbamazepine ErCarbamazepine | 35 | $5,121 |
| Lamotrigine | 92 | $2,087 |
| Lamotrigine ErLamotrigine | 14 | $1,695 |
| Zonisamide | 69 | $1,123 |
| Lacosamide | 15 | $911 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $767 |
| Topiramate | 48 | $672 |
| Phenobarbital | 11 | $310 |
| Divalproex Sodium | 17 | $300 |
| Clonazepam | 20 | $200 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Kalispell
- Elizabeth WoodBillings$742
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.